Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue, net | -95,217 | NaN | 139,352 | NaN |
| Cost of sales (excluding stock-based compensation) | -41,548 | NaN | 63,219 | NaN |
| Amortization - license & ip expense | -974 | NaN | 1,455 | NaN |
| Sales (excluding stock-based compensation) | -15,833 | NaN | 24,646 | NaN |
| Marketing (excluding stock-based compensation) | -6,168 | NaN | 8,221 | NaN |
| Research and development (excluding stock-based compensation) | -14,760 | NaN | 23,401 | NaN |
| General and administrative (excluding stock-based compensation) | -18,062 | NaN | 34,140 | NaN |
| Stock-based compensation expense | -14,198 | NaN | 19,059 | NaN |
| Other segment items | 12,729 | NaN | -12,326 | NaN |
| Net loss | -18,866 | -44,076 | -5,478 | -16,985 |
| Depreciation and amortization | 1,865 | 1,896 | 1,918 | 3,765 |
| Amortization of operating lease-right-of use assets | 948 | 1,147 | 1,142 | 2,107 |
| Stock-based compensation | 4,861 | 5,527 | 5,638 | 13,420 |
| Loss on disposal of property and equipment | -55 | -60 | -102 | -253 |
| Provision for credit losses | 459 | 311 | 50 | 52 |
| Provision for excess and obsolete inventory | 193 | 1,236 | 132 | 335 |
| Deferred income taxes | -183 | 38,576 | -2,627 | -2,392 |
| Gain on investments, accretion, and amortization, net | -1,255 | -1,212 | -1,353 | -3,108 |
| Interest expenses for accretion of the legal settlement liabilities | -47 | -761 | 141 | 292 |
| Other non-cash expense (income), net | -236 | NaN | NaN | NaN |
| Trade accounts receivable | -9,645 | 6,146 | 587 | -7,101 |
| Inventories | 1,627 | -2,051 | 2,222 | 5,073 |
| Prepaid expenses and other assets | -3,853 | 3,353 | -1,114 | 419 |
| Trade accounts payable | 390 | -1,309 | 588 | 1,169 |
| Accrued expenses and other liabilities | -3,890 | 4,709 | -1,409 | 670 |
| Legal settlement liabilities | -389 | -293 | -252 | -588 |
| Operating lease liabilities | 3,117 | NaN | -1,079 | -2,197 |
| Deferred revenue | 1,175 | 1,736 | 284 | 1,581 |
| Lease liabilities | NaN | 4,146 | NaN | NaN |
| Net cash (used in) operating activities | -2,736 | -771 | -3,898 | -17 |
| Purchases of marketable securities | -95,598 | -77,108 | -59,624 | -141,423 |
| Proceeds from maturities of marketable securities | 70,714 | 76,105 | 79,200 | 136,906 |
| Proceeds from sale of property and equipment | 6 | 195 | 1 | 56 |
| Acquisition of business | NaN | 0 | NaN | NaN |
| Purchase of property and equipment | 2,168 | 1,001 | 657 | 2,426 |
| Purchase of intangible assets | 33 | 32 | -2 | 76 |
| Payment for additional investment in cytek japan, net of cash acquired | NaN | 0 | NaN | NaN |
| Net cash (used in) provided by investing activities | -27,079 | -1,842 | 18,920 | -6,961 |
| Repayment of loan | 869 | 2,940 | 145 | 1,660 |
| Proceeds from employee stock purchase plan | NaN | 446 | 0 | 703 |
| Payments for taxes related to net share settlement of equity awards | 239 | 268 | 171 | 231 |
| Proceeds from issuance of common stock under employee stock plans | 21 | 85 | 137 | 103 |
| Proceeds from line of credit | 5,068 | 1,416 | 2,091 | 2,075 |
| Payments for repurchase of shares | 0 | -34 | -29 | 15,137 |
| Net cash provided by (used in) financing activities | 3,981 | -1,226 | 1,941 | -14,147 |
| Effect of exchange rate changes on cash and cash equivalents | 646 | 1,412 | 846 | -2,149 |
| Net (decrease) in cash and cash equivalents | -25,188 | -2,427 | 17,810 | -23,275 |
| Cash and cash equivalents at beginning of period | 90,853 | 93,281 | 98,745 | NaN |
| Cash and cash equivalents at end of period | 65,665 | 90,853 | 93,281 | NaN |